Nahed Jalloul, Ph.D.
Introduction
I’m a Principal Scientist in Applied & Translational Omics at GSK, focused on uncovering the drivers of PD to support the company’s mission of improving patient health. My work integrates genomics, transcriptomics, proteomics, and metabolomics to map the complex biology of the disease. By turning multi-omics insights into actionable targets and biomarkers, I help advance GSK’s pipeline and accelerate development of more effective, patient-centered therapies.
AMP PD Datasets & the Verily Workbench
I’ve analyzed multiple AMP PD datasets, including single nucleus RNAseq from brain tissue and whole genome sequencing, to investigate how specific gene mutations linked to Parkinson’s drive disease phenotypes. Using this data, I characterize affected cell types and molecular pathways and prioritize targets based on evidence of disease relevance. On the Verily Workbench I leveraged the secure, cloud-based environment for scalable computing, reproducible workflows, and integrated data management- running large scale analyses, sharing notebooks and pipelines with collaborators, and versioning results to support traceability beyond the pilot.
Impact of the AMP PD Resources in My Work
The AMP PD resource has become a foundational dataset for Parkinson’s research, enabling integrated interrogation of transcriptomics, genomics, proteomics, and clinical metadata to inform therapeutic strategies. Its multi-omics breadth gives a comprehensive view of disease biology across molecular layers, helping to reveal mechanisms relevant to both early intervention and later stage disease modification. This holistic perspective supports robust target and biomarker prioritization and derisking of therapeutic hypotheses. Overall, AMP PD accelerates translational research by providing high quality, interoperable data that enhances our ability to develop patient centered treatments.